Association of pharmacokinetic biomarkers with early immune recovery following HLA-haploidentical hematopoietic cell transplantation
The relationship of pharmacokinetic biomarkers to immune and clinical outcomes warrants further investigation in larger studies but holds promise for personalizing dosing of GVHD prophylaxis to improve patient outcomes after alloHCT.
Authors
- Guofang Shen (ORCID: https://orcid.org/0000-0001-6653-0440)
- Timothy W. Synold (ORCID: https://orcid.org/0000-0002-4075-2544)
- Shazia Khan (ORCID: https://orcid.org/0000-0003-1738-3418)
- David Horne (ORCID: https://orcid.org/0000-0002-9300-1082)
- Christopher George Kanakry (ORCID: https://orcid.org/0000-0002-7736-2056)
- R. Nakamura
Institutions
- City of Hope (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-05
- DOI
- https://doi.org/10.3389/fimmu.2025.1694754
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00